Non-steroidal Anti-inflammatory Drugs Market Share Analysis Report, 2023-2032
The non-steroidal anti-inflammatory drugs market size was estimated at USD 21,207.15 million in 2022 and is expected to surpass around USD 35,780.96 million by 2032 and poised to grow at a compound annual growth rate (CAGR) of 5.37% during the forecast period 2023 to 2032.
Key Takeaways:
Non-steroidal Anti-inflammatory Drugs Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 22,345.97 million |
| Market Size by 2032 | USD 35,780.96 million |
| Growth Rate From 2023 to 2032 | CAGR of 5.37% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Disease indication, Route of administration, Distribution Channel, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Pfizer Inc.; Bayer AG; GSK plc; Dr. Reddy’s Laboratories Ltd; Viatris Inc; Teva Pharmaceutical Industries Ltd.; Johnson And Johnson Services; Inc.; Merck & Co., Inc. |
Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.
The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.
Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.
Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy’s Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.
Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.
Disease Indication Insights
The arthritis segment held the largest market share of 40.02% in 2022 and is expected to maintain its dominance over the forecast period. The growth of the segment is owing to factors such as the high prevalence of arthritis and osteoarthritis, the rising geriatric population across the globe, the high prescription of NSAIDs, and a surge in the adoption of topical preparations for subsiding arthritis. According to the Arthritis Society Canada, in 2019, Canada had over 6 million arthritis cases and is expected to be around 9 million by 2040. Moreover, the availability of many approved formulations for the management of arthritis pain is also expected to spur the arthritis segment growth. For instance, Celebrix (Celecoxib Capsule), manufactured by Viatris Inc., is indicated for pain management in rheumatoid arthritis and osteoarthritis.
The migraine segment is expected to witness lucrative growth opportunities during the forecast period owing to the high prevalence of migraines and approved formulations for them. For instance, Advil migraine (Ibuprofen Capsule) manufactured by GSK plc is the only U.S. FDA-approved regime for migraine episodes. Moreover, increasing the adoption of over-the-counter non-steroidal anti-inflammatory drugs is further propelling the segment growth over the forecast period.
Route of Administration Insights
The oral segment held the largest market share in 2022 and is expected to maintain its dominance over the forecast period owing to the availability of a large pool of oral NSAIDs for pain, headache, fever, and migraine and increased sales of OTC NSAIDs. For instance, Johnson & Johnson Consumer Inc. offers its NSAID preparation Motrin (ibuprofen), which is available in dosage forms such as a tablet, capsule, liquid gel, and suspension to treat headaches and migraines. Thus, owing to the higher availability of oral NSAIDs products, the segment is expected to experience robust growth opportunities during the forecast period.
The topical segment is expected to experience the fastest growth rate over the forecast period. The wide availability of topical NSAID preparations and high demand for topical drugs are expected to fuel the growth over the forecast period. For instance, Flector (diclofenac epolamine-Topical system) manufactured by IBSA Pharma Inc., is indicated for pains due to sprains and strains.
Distribution Channel Insights
The retail pharmacy segment held the largest market share of 48.39% in 2022. The high market share of retail pharmacies can be attributed to factors such as the increasing number of NSAIDs prescriptions for pain management and the rising availability of NSAIDs as over-the-counter drugs across the globe. For instance, In August 2021, Dr. Reddy’s Laboratories Ltd re-launched OTC Naproxen Sodium Tablets USP, the store-brand equivalent of Aleve in the United States.
Furthermore, hospital pharmacies held the second largest market share owing to the high adoption rate of non-steroidal anti-inflammatory drugs for pain management in hospitalized patients. However, the online pharmacy segment is expected to grow at the fastest rate during the forecast period, owing to factors, such as increasing adoption of e-commerce and extra discounts on online medicines.
Regional Insights
North America dominated the overall market in terms of revenue in 2022, followed by Europe. Factors such as the presence of a large number of manufacturers and strategic initiatives undertaken by market players are some of the major factors driving the market's growth. Moreover, the increasing prevalence of chronic pain and arthritis is also anticipated to propel the growth forward during the forecast period.
For instance, according to the CDC, it is estimated that the prevalence of arthritis is expected to increase in the upcoming decades. By 2040, it is estimated that over 78.4 million adults will have doctor-diagnosed arthritis. Moreover, the major market players operating in the NSAIDs market have a decent presence across the region, and that is likely to propel market growth forward during the forecast period. For instance, Pfizer Inc., Johnson & Johnson Consumer Inc., and GSK Group of Companies have a decent presence across the United States and Canada.
Asia-Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region is attributed to factors such as the increasing geriatric population, the rising prevalence of chronic pain, migraine, and headaches, along with rising product approvals and launches in the region. For instance, in May 2021, Ono Pharmaceutical Co., Ltd. launched JOYCLU 30mg intra-articular injection, for which Seikagaku received manufacturing and marketing approval in Japan in March 2021.
Some of the prominent players in the Non-steroidal Anti-inflammatory Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Non-steroidal Anti-inflammatory Drugs market.
By Disease Indication
By Route of Administration
By Distribution Channel
By Region
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Nova one advisor Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: commodity flow approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Non-Steroidal Anti-Inflammatory Drugs Market Variables, Trends & Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Increasing Geriatric Population
3.1.1.2 Increasing Prevalence of Targeted Diseases
3.1.2 Market Restraint Analysis
3.1.2.1 Side-effects Associated with NSAIDs
3.2 Penetration and Growth Prospect Mapping
3.3 Business Environment Analysis Tools
3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.3.2 Porter’s Five Forces Analysis
3.3.3 Industry Analysis - Ansoff Matrix
3.4 Pricing Analysis
3.5 Regulatory Scenario
Chapter 4 Regulatory & Political Forces
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Heat map analysis
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2021
4.4 Public Companies
4.4.1 Company market position analysis
4.4.1.1 Market Differentiators
4.5 Private Companies
4.5.1 List of key emerging companies
4.6 Major Deals and Strategic Alliances Analysis
4.6.1 New Product Launch
4.6.2 Acquisitions
4.6.3 Expansion
4.6.4 Licensing and Partnerships
Chapter 5 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Disease indication, 2020 - 2032
5.1 Disease Indication Market Share Analysis, 2023 - 2032
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2020 - 2032
5.3.1 Arthritis
5.3.1.1 Arthritis market estimates and forecast, 2020 - 2032
5.3.2 Migraine
5.3.2.1 Migraine market estimates and forecast, 2020 - 2032
5.3.3 Ophthalmic Diseases
5.3.3.1 Ophthalmic diseases market estimates and forecast, 2020 - 2032
5.3.4 Others
5.3.4.1 Other market estimates and forecast, 2020 - 2032
Chapter 6 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Route of Administration, 2020 - 2032
6.1 Route of Administration Market Share Analysis, 2023 - 2032
6.2 Segment Dashboard
6.3 Market Size & Forecasts and Trend Analysis, 2023 - 2032
6.3.1 Oral
6.3.1.1 Oral market estimates and forecast, 2020 - 2032
6.3.2 Topical
6.3.2.1 Topical market estimates and forecast, 2020 - 2032
6.3.3 Others
6.3.3.1 Other market estimates and forecast, 2020 - 2032
Chapter 7 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Distribution Channel, 2020 - 2032
7.1 Distribution Channel Market Share Analysis, 2023 - 2032
7.2 Segment Dashboard
7.3 Market Size & Forecasts and Trend Analysis, 2023 - 2032
7.3.1 Hospital Pharmacy
7.3.1.1 Hospital pharmacy market estimates and forecast, 2020 - 2032
7.3.2 Retail Pharmacy
7.3.2.1 Retail pharmacy market estimates and forecast, 2020 - 2032
7.3.3 Online Pharmacy
7.3.3.1 Online pharmacy market estimates and forecast, 2020 - 2032
Chapter 8 Non-Steroidal Anti-Inflammatory Drugs Market - Segment Analysis, By Region, 2020 - 2032
8.1 Regional Market Share Analysis, 2023 - 2032
8.2 Regional Market Dashboard
8.3 North America
8.3.1 North America market estimates and forecast, 2020 - 2032
8.3.2 U.S.
8.3.2.1 U.S. market estimates and forecast, 2020 - 2032
8.4 Canada
8.4.1. Canada market estimates and forecast, 2020 - 2032
8.5 Europe
8.5.1 Europe market estimates and forecast, 2020 - 2032
8.5.2 Germany
8.5.2.1 Germany market estimates and forecast, 2020 - 2032
8.5.3 UK
8.5.3.1 UK market estimates and forecast, 2020 - 2032
8.5.4 Spain
8.5.4.1 Spain market estimates and forecast, 2020 - 2032
8.5.5 France
8.5.5.1 France market estimates and forecast, 2020 - 2032
8.5.6 Italy
8.5.6.1 Italy market estimates and forecast, 2020 - 2032
8.6 Asia Pacific
8.6.1 Asia Pacific market estimates and forecast, 2020 - 2032
8.6.2 Japan
8.6.2.1 Japan market estimates and forecast, 2020 - 2032
8.6.3 China
8.6.3.1 China market estimates and forecast, 2020 - 2032
8.6.4 India
8.6.4.1 India market estimates and forecast, 2020 - 2032
8.6.5 South Korea
8.6.5.1 South Korea market estimates and forecast, 2020 - 2032
8.6.6 Australia
8.6.6.1 Australia market estimates and forecast, 2020 - 2032
8.7 Latin America
8.7.1 Latin America market estimates and forecast, 2020 - 2032
8.7.2 Brazil
8.7.2.1 Brazil market estimates and forecast, 2020 - 2032
8.7.3 Mexico
8.7.3.1 Mexico market estimates and forecast, 2020 - 2032
8.7.4 Argentina
8.7.4.1 Argentina market estimates and forecast, 2020 - 2032
8.8 Middle East & Africa
8.8.1 Middle East & Africa market estimates and forecast, 2020 - 2032
8.8.2 South Africa
8.8.2.1 South Africa market estimates and forecast, 2020 - 2032
8.8.3 UAE
8.8.3.1 UAE market estimates and forecast, 2020 - 2032
8.8.4 Saudi Arabia
8.8.4.1 Saudi Arabia market estimates and forecast, 2020 - 2032
Chapter 9 Competitive & Vendor Landscape
9.1 Participant Categorization
9.1.1 Innovators
9.1.2 Market Leaders
9.2 Strategy Mapping
9.2.1 Key Strategies Chosen by Players in this Market Include:
9.2.1.1 Launch of new products
9.2.1.2 Acquisition
9.2.1.3 Expansion
9.2.1.4 Agreements, collaborations, partnerships
9.2.1.5 Others (realignment, divestment, market penetration):
9.3 Strategic Framework
9.3.1 Key Company Market Share Analysis, 2021
9.4 Company Profiles
9.4.1 Pfizer Inc.
9.4.1.1 Company overview
9.4.1.2 Financial performance
9.4.1.3 Product benchmarking
9.4.1.4 Strategic initiatives
9.4.2 Bayer AG
9.4.2.1 Company overview
9.4.2.2 Financial performance
9.4.2.3 Product benchmarking
9.4.2.4 Strategic initiatives
9.4.3 GSK plc
9.4.3.1 Company overview
9.4.3.2 Financial performance
9.4.3.3 Product benchmarking
9.4.3.4 Strategic initiatives
9.4.4 Dr. Reddy’s Laboratories Ltd
9.4.4.1 Company overview
9.4.4.2 Financial performance
9.4.4.3 Product pipeline
9.4.4.4 Strategic initiatives
9.4.5 Viatris Inc
9.4.5.1 Company overview
9.4.5.2 Financial performance
9.4.5.3 Product pipeline
9.4.5.4 Strategic initiatives
9.4.6 Teva Pharmaceutical Industries Ltd.
9.4.6.1 Company overview
9.4.6.2 Product benchmarking
9.4.6.3 Strategic initiatives
9.4.7 Johnson and Johnson Services, Inc.
9.4.7.1 Company overview
9.4.7.2 Financial performance
9.4.7.3 Product benchmarking
9.4.8 Merck & Co., Inc.
9.4.8.1 Company overview
9.4.8.2 Financial performance
9.4.8.3 Product benchmarking
9.4.8.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers